Abstract: A method of dosing multiple drugs for an individual patient, by collecting data from the individual patient including drugs to be taken by the patient and genetic testing information, analyzing the individual patient data in view of dosing criteria established based on outside patient data, and determining doses of multiple drugs for each drug taken by the individual patient. A logic engine for dosing multiple drugs, including an algorithm stored on non-transitory computer readable media for collecting outside data to establish criteria for dosing multiple drugs to an individual patient and storing the outside data and individual patient data in a database, analyzing the individual patient data in view of criteria established from the outside data, and determining a dose for each drug to be taken.

Abstract: The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.

Abstract: An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.

Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.

Abstract: Cell culture mediums for generating organoids, including tumour organoids. Specifically, such mediums comprise: a cell culture medium; an antioxidant; a serum free supplement; an insulin receptor agonist; a glucocorticoid; and an FGFR agonist. Other aspects involve methods of generating tumour organoids from tumours. Such methods can comprise generating pancreatic progenitor organoids from pluripotent stem cells, pancreatic lineage committed progenitors.

Abstract: The present invention is directed to a cuff-like medical device that may analyze and report the concentrations of various biomarkers in a subject's bodily fluids, samples of which may be extracted by the device in the field and analyzed on the spot using the cuff-like medical device. For example, extracellular fluid (commonly known as “tissue fluid”) of a patient may be analyzed by the present invention, and in particular, the constituent interstitial fluid—the known main component of extracellular fluid—may be analyzed for concentrations of one or more specific types of proteins. A sensor component within the device may include one or more aptamers that permit chemical binding of at least one biomarker of interest. When the aptamer-protein binding complex is complete, an electronic component of the device may employ nanoscale weighing using frequency differential analysis through quartz crystal microbalances to determine the presence and concentration of biomarkers.

Abstract: Methods and apparatus of some aspects of the invention relate to the synthesis of high fidelity polynucleotides. In particular, aspects of the invention relate to concurrent enzymatic removal of amplification sequences and ligation of processed oligonucleotides into nucleic acid assemblies. According to some embodiments, the invention provides a method for producing a target nucleic acid having a predefined sequence. In some embodiments, the method comprises the step of providing a plurality of oligonucleotides, wherein each oligonucleotides comprises (i) an internal sequence identical to a different portion of a sequence of a target nucleic acid, (ii) a 5? sequence flanking the 5? end of the internal sequence and a 3? flanking sequence flanking the 3? end of the internal sequence, each of the flanking sequence comprising a primer recognition site for a primer pair and a restriction enzyme recognition site.

Abstract: The present invention relates to a method for producing CRM197 recombinant protein in cells. The method comprises culturing a cell comprising an expression plasmid with a polynucleotide and inducing expression of the CRM197 protein.

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.

Abstract: The present invention discloses a method for analysis of drug resistance of tumor cells. The method includes the steps of: (a) providing silicon dioxide nanoparticles, polystyrene-co-polyacrylic acid nanoparticles or metal-organic framework nanoparticles; (b) co-incubating the silicon dioxide nanoparticles, the polystyrene-co-polyacrylic acid nanoparticles or the metal-organic framework nanoparticles with the tumor cells; and (c) detecting endocytosis of the silicon dioxide nanoparticles, the polystyrene-co-polyacrylic acid nanoparticles or the metal-organic framework nanoparticles by the tumor cells. The analysis method of the present invention can analytically identify drug-resistant tumor cells in a clear, intuitive and efficient way. The provided nanoparticles feature simple synthesis processes that take short periods of time, and after they are co-incubated with the tumor cells, a flow cytometer is used for detection.

Abstract: An amplification data display method according to the present invention comprises the steps of: displaying a plate display area and an integrated data display area; displaying, in the plate display area, plates where nucleic acid amplification reactions have been performed; and displaying amplification data in the integrated data display area, wherein: two or more plates are displayed in the plate display area; each of the plates includes a plurality of reaction wells; the amplification data are generated from the reaction wells by the nucleic acid amplification reactions; and amplification data for a plurality of reaction wells selected from the reaction wells of two or more of the displayed plates are displayed in the integrated data display area.

Abstract: The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.

Abstract: A method of determining a clinical value for an individual based on a tumor in an image by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to determine a lymphocyte distribution of lymphocytes in the tumor based on the image; apply a classifier to the lymphocyte distribution to classify the tumor, the classifier having been trained to classify tumors into a class selected from at least two classes respectively associated with lymphocyte distributions; and determine the clinical value for the individual based on prognoses of individuals with tumors in the class into which the classifier classified the tumor.

Abstract: Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a terpenyl group attached via an ester or amide linkage and at least one R1-R18, (e.g., R3, R7 and R12) is an amino acid linked to the steroidal backbone by an ester or amide linkage: R18 has the following structure: —R19—(C?O)—X—R20 ?where R19 is omitted or alkyl, alkenyl, alkynyl, or aryl, X is oxygen or nitrogen, and R20 is a terpenyl group. R3, R7 and R12 have the following structure: R22R23N—R21—(C?O)—X— ?where R21 is substituted or unsubstituted alkyl, X is oxygen or nitrogen, and R22 and R23 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl.

Abstract: This invention relates generally to devices, systems, and methods for performing biological assays by using indicators that modify one or more optical properties of the assayed biological samples. The subject methods include generating a reaction product by carrying out a biochemical reaction on the biological sample introduced into a device and reacting the reaction product with an indicator capable of generating a detectable change in an optical property of the biological sample to indicate the presence, absence, or amount of analyte suspected to be present in the sample.

Abstract: Fluorescent viral particles, including viral particles and a fluorescent dye conjugated to the viral particles, are used for viral contaminant removal testing as part of viral clearance evaluation for biological medical product preparation processes. The conjugated fluorescent dye adds only marginally to viral particle size, but provides versatility both for rapid screening of alternative viral removal approaches during process development and for final process validation, as the fluorescent viral particles have fluorescent activity throughout the viral clearance evaluation process, permitting rapid and consistent quantification of initial test solutions, resulting purified solutions, and intermediate solutions of interest at any point during processing under evaluation.

Abstract: In flow cytometry evaluation for unassociated virus-size particles stained with multiple fluorogenic dyes, the fluid sample is stained with an aqueous diluted dye formulation including multiple fluorogenic dyes. Preparation of the aqueous diluted dye formulation includes first preparatory processing to prepare a concentrated dye formulation with the fluorogenic dyes provided in a dry powder mixture mixed with and dissolved into a first liquid medium comprising DMSO. After the first preparatory processing, aqueous liquid diluent is added to dilute the first liquid medium and while the fluorogenic dyes remain in solution the liquid medium is converted to an aqueous liquid medium, which may include DMSO as a minor molar component but at a significant concentration. The stained fluid sample may include dissolved disaccharide.

Abstract: Provided herein are devices for monitoring nucleic acid amplification, nucleic acid amplification monitors, methods of quantifying nucleic acid amplification, methods of identifying an unknown nucleic acid molecule, and systems for monitoring nucleic acid amplification. The disclosed devices, methods, and systems comprise at least one nuclemeter, comprising at least one sample chamber and at least one reaction-diffusion conduit in fluid communication with the chamber.

Abstract: A method of operation of a compute system includes: detecting a skin area in a patient image; segmenting the skin area into a segmented image having an acne pimple at the center; generating a target pixel array from the segmented image includes separating a plurality of the acne pimples that are adjacent in the segmented image; identifying an acne characterization of the acne pimples including an area of each acne and an acne score; and assembling a user interface display from the acne characterization for displaying on a device.

Abstract: In some embodiments, provided herein is an integrated assay of a biological sample comprising an in situ assay module and a spatial assay module. The in situ assay comprises analyzing binding between nucleic acid probes and a first analyte at a spatial location of the biological sample. In some embodiments, the method further comprises providing conditions to allow spatially barcoded capture agents to capture a second analyte for analysis in the spatial assay module.

Abstract: Disclosed herein are circular zymogens of RNase 1 that have a proteolytic cleavage site and are activated by a specific protease. These circular zymogens are useful for treatment of disorders that are characterized by a specific protease (e.g., HTV-1 protease).

Abstract: The present invention provides oligonucleotides and methods for their use in the detection and/or differentiation of target nucleic acids. The oligonucleotides and methods find particular application in amplifying, detecting, and/or discriminating multiple targets simultaneously.

Abstract: The present invention relates to an immunogenic polypeptide comprising (i) a B-cell epitope, (ii) a T-cell epitope, and (iii) a scaffold polypeptide, wherein said scaffold polypeptide is a thioredoxin polypeptide. The present invention further relates to said immunogenic polypeptide for use in medicine and for use in treating and/or preventing inappropriate proliferation of cells and/or infection with an infectious agent, preferably HPV infection, as well as to polypeptides and vectors encoding said immunogenic polypeptide.

Abstract: SARS-CoV-2 causes pandemic COVID19. Developing an effective treatment to directly target the virus could significantly impact viral burden in those most vulnerable to the devastating effects of this virus. The invention provides antisense oligonucleotides (AOs) to target the single stranded RNA genome of the SARS-CoV-2 viruses. The administration of AOs can significantly reduce the target viral RNAs.

Abstract: The present disclosure relates to methods and systems for assessing the quality of a meat product. In certain embodiments, the present disclosure provides a method of assessing quality of a meat product, the method comprising receiving data representative of light emitted from the meat product upon application of incident light to the meat product, analysing the data to determine one or more parameters indicative of quality of the meat product, and assessing the quality of the meat product on the basis of the one or more parameters.

Abstract: The present disclosure relates to the field of medical diagnosis, and specifically, relates to a synthetic peptide for detecting HIV-1. The synthetic peptide is obtained by mutating the amino acid sequence set forth as SEQ ID NO: 1. The synthetic peptide can better detect anti-HIV-1 antibodies, and can better avoid potential “false negative” and “false positive” results.

Abstract: A photonic biosensor including a biological probe disposed on a mid-infrared-transparent waveguide can be used to detect biological analytes in biological samples, using specific binding of the analyte to the probe in conjunction with absorption spectroscopy. In various embodiments, the biosensor is used for molecular diagnostics, e.g., to detect oligonucleotides or proteins associated with a coronavirus.

Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.

Abstract: Disclosed herein are system, method, and computer program product embodiments for optimizing the determination of a phenotypic impact of a molecular variant identified in molecular tests, samples, or reports of subjects by way of regularly incorporating, updating, monitoring, validating, selecting, and auditing the best-performing evidence models for the interpretation of molecular variants across a plurality of evidence classes.

Abstract: An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of a coronavirus. The coronavirus may be SARS-CoV-2 or another ?CoV. The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating coronavirus-mediated disease, a method of preventing coronavirus-mediated disease, a method of reducing or preventing the replication of coronavirus in a host cell, a method of controlling the spread of coronavirus in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or coronavirus-mediated disease.

Abstract: The invention relates to a lateral flow assay device for the detection of a target peptide in a liquid sample, comprising: (a) a solid support, (b) a sample pad for initially receiving and optionally pre-treating the sample at a first end of the solid support, (c) an absorbent pad at a second end of the solid support, (d) a conjugate pad comprising in a dry state a mobilizable conjugate of a particle and the target peptide, wherein the target peptide conjugated to said particle is biotinylated and the particle comprises on its surface a biotin-binding protein, (e) a target peptide reaction membrane comprising, (i) a capture region comprising an immobilized first capture reagent against the target peptide, and (ii) optionally a control region comprising an immobilized second capture reagent against particle control conjugate, wherein the sample pad, the conjugate pad, the reaction membrane and the absorbent pad are mounted to the solid support to permit capillary flow from the sample pad to the reaction membra

Abstract: A non-invasive, transcutaneous, real-time viral detection device that is configured for self-administration, e.g., at a user's home. In one embodiment, and after positioning the device relative to the human body part (e.g., the user's finger), light sources in the device are activated (excited), and resulting data captured. In particular, a set of Raman spectra are collected from a configured set of emitters and detectors in the device and delivered to a nearby receiver, preferably wirelessly. The receiver filters and de-convolves the Raman spectra producing a data set representative of the constituent elements in the user's tissue of interest. The data set is applied against a statistical classifier, e.g., a neural network that has been trained to recognize and distinguish the absence or presence of viral components, e.g., C-19, or its associated blood-borne acute phase reactants.

Abstract: Low molecular weight molecules able to penetrate cells and tissues and having high specificity and affinity for the surfaces of proteins. Methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers, infectious diseases, and diseases and disorders associated with aberrant protein expression using same. A method for selecting a therapeutic peptide for binding to an isolated and/or purified protein of interest by screening a phage display library containing phage particles with phage display peptides which have at least one APBA modified cysteine residue. The APBA modified cysteine residues bind to surface lysine residues on the isolated and/or purified protein of interest by dynamic covalent conjugation to form iminoboronates.

Abstract: The quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample, in particular human serum and/or Cerebrospinal Fluid (CSF) is detailed. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved and an in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved are detailed. A kit to quantitate the specific antibodies for at least one redox form of HMGB1, in particular human HMGB1 is detailed.

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

Abstract: Embodiments of apparatuses, systems, methods for monitoring wound pH are disclosed. In some embodiments, a wound dressing includes one or more optical sensors configured to measure a change in color of a pH-sensitive adhesive that changes color in response to changes in wound exudate pH. In some embodiments, the wound dressing may further comprise hydrophilic channels that direct wound exudate to a pH-sensitive material over the optical sensors. Such dressings may also be used in combination with a negative pressure wound therapy system.

Abstract: Systems, methods, and collection devices are disclosed for rapid, local PCR testing. The PCR testing system may be configured for use with a disposable sample collection device that includes a swab configured for collecting a biological sample from a patient; and a sample container configured to receive the swab and separate a bulk quantity of the biological sample from the swab for containment in a bulk collection chamber, which is located with the sample container, wherein the sample container is configured to meter a selected volume of the biological sample into a PCR sample tube, which contains a lyophilized master mix, releasably attachable to the sample container.

Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.

Abstract: Provided herein are compositions, methods, devices, and systems for highly accurate and pure RNA synthesis. Also provided herein are nucleic acid libraries comprising RNAs generated by using devices, compositions and methods disclosed herein.

Abstract: One example of a flow cell includes a base support and a multi-layer stack positioned over the base support. The multi-layer stack includes a resin layer positioned over the base support; and a hydrophobic layer positioned over the resin layer. A depression is defined in the multi-layer stack through the hydrophobic material and through a portion of the resin.

Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

Abstract: This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Abstract: The invention features methods, systems, and cartridges for amplification of target nucleic acids in complex samples, for example, whole blood. The invention also features diagnostic and therapeutic methods based on amplification of target nucleic acids characteristic of pathogens present in complex samples containing cells and/or cell debris, for example, whole blood.

Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

Abstract: Embodiments described herein may be useful in the detection of analytes. The systems and methods may allow for a relatively simple and rapid way for detecting analytes such as chemical and/or biological analytes and may be useful in numerous applications including sensing, food manufacturing, medical diagnostics, performance materials, dynamic lenses, water monitoring, environmental monitoring, detection of proteins, detection of DNA, among other applications. For example, the systems and methods described herein may be used for determining the presence of a contaminant such as bacteria (e.g., detecting pathogenic bacteria in food and water samples which helps to prevent widespread infection, illness, and even death). Advantageously, the systems and methods described herein may not have the drawbacks in current detection technologies including, for example, relatively high costs, long enrichment steps and analysis times, and/or the need for extensive user training.

Abstract: The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

Abstract: Embodiments relate to predicting height information for an object. First distance data is determined at a first time when an object is at a first position that is only partially within the field-of-view. Second distance data is determined at a second, later time when the object is at a second, different position that is only partially within the field-of-view. A distance measurement model that models a physical parameter of the object within the field-of-view is determined for the object based on the first and second distance data. Third distance data indicative of an estimated distance to the object prior to the object being entirely within the field-of-view of the distance sensing device is determined based on the first distance data, the second distance data, and the distance measurement model. Data indicative of a height of the object is determined based on the third distance data.

Abstract: A method and system are disclosed for detecting microbial pathogens in a sample suspected of containing the pathogens. The method includes combining loop-mediated isothermal amplification (LAMP) reagents and a polymer gel, such as a hydrogel, together with the sample to form a mixture. The gel polymerizes over a short time to immobilize the viral particles within the mixture. If target DNA/RNA are present in the sample, amplicons are produced. The target microorganisms are detected by visually detecting the presence or absence of the amplicons. The target microorganism concentrations may be determined based on the number of fluorescent amplicon dots after the reaction using a smartphone or a fluorescent microscope. The method may be employed for rapidly and inexpensively quantifying microbial pathogens in environmental water samples with high sensitivity.

Abstract: An example method for training a graph convolutional neural network (GCNN) configured for virtual screening of molecules for drug discovery is described herein. The method can include receiving a first data set including a plurality of molecules, and training the GCNN to initialize one or more parameters of the GCNN using the first data set. The method can also include receiving a second data set including a plurality of molecules and respective inhibition rates for a disease, and training the GCNN to refine the one or more parameters of the GCNN using the second data set. The molecules in the first and second data sets can be expressed in a computer-readable format. An example method for virtually screening molecules on Plasmodium falciparum (P. falciparum) is also described herein.